Evidence map›Paper›PMID 19444933›Full record

ArticleThe Journal of steroid biochemistry and molecular biology2009

Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.

Robert Clarke, Ayesha N Shajahan, Rebecca B Riggins, Younsook Cho, Anatasha Crawford, Jianhua Xuan, Yue Wang, Alan Zwart, Ruchi Nehra, Minetta C Liu

Open access · greenAbstract read
In one paragraph

Article in The Journal of steroid biochemistry and molecular biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Exploring new pathways in endocrine-resistant breast cancer.Exploration of targeted anti-tumor therapy · 2022
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Endocrine resistance in breast cancer--An overview and update.Molecular and cellular endocrinology · 2015
    Review
  14. Article
  15. Article
  16. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.Journal of experimental & clinical cancer research : CR · 2015
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Robert ClarkeDepartment of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20057, USA. clarker@georgetown.edu
Ayesha N Shajahan
Rebecca B Riggins
Younsook Cho
Anatasha Crawford
Jianhua Xuan
Yue Wang
Alan Zwart
Ruchi Nehra
Minetta C Liu
Georgetown University Medical Center · USGeorgetown University · USVirginia Tech · US

Funding

TRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8M
Timing of dietary exposure and breast cancer riskU54CA100970 · NCI · GEORGETOWN UNIVERSITY · PI HILAKIVI-CLARKE, LEENA A. · 2003 to 2008
$7.2M
Molecular Analysis of Human Breast CancerR01CA096483 · NCI · GEORGETOWN UNIVERSITY · PI CLARKE, ROBERT R. · 2003 to 2007
$2.5M
NCI NIH HHS R01 CA096483NCI NIH HHS T32 CA009686NCI NIH HHS U54 CA100970
6 · The paper itself

Abstract

Resistance to endocrine therapies, whether de novo or acquired, remains a major limitation in the ability to cure many tumors that express detectable levels of the estrogen receptor alpha protein (ER). While several resistance phenotypes have been described, endocrine unresponsiveness in the context of therapy-induced tumor growth appears to be the most prevalent. The signaling that regulates endocrine resistant phenotypes is poorly understood but it involves a complex signaling network with a topology that includes redundant and degenerative features. To be relevant to clinical outcomes, the most pertinent features of this network are those that ultimately affect the endocrine-regulated components of the cell fate and cell proliferation machineries. We show that autophagy, as supported by the endocrine regulation of monodansylcadaverine staining, increased LC3 cleavage, and reduced expression of p62/SQSTM1, plays an important role in breast cancer cells responding to endocrine therapy. We further show that the cell fate machinery includes both apoptotic and autophagic functions that are potentially regulated through integrated signaling that flows through key members of the BCL2 gene family and beclin-1 (BECN1). This signaling links cellular functions in mitochondria and endoplasmic reticulum, the latter as a consequence of induction of the unfolded protein response. We have taken a seed-gene approach to begin extracting critical nodes and edges that represent central signaling events in the endocrine regulation of apoptosis and autophagy. Three seed nodes were identified from global gene or protein expression analyses and supported by subsequent functional studies that established their abilities to affect cell fate. The seed nodes of nuclear factor kappa B (NFkappaB), interferon regulatory factor-1 (IRF1), and X-box binding protein-1 (XBP1)are linked by directional edges that support signal flow through a preliminary network that is grown to include key regulators of their individual function: NEMO/IKKgamma, nucleophosmin and ER respectively. Signaling proceeds through BCL2 gene family members and BECN1 ultimately to regulate cell fate.

Indexed as

Breast NeoplasmsDrug Resistance, NeoplasmAnimalsApoptosisApoptosis Regulatory ProteinsAutophagyBeclin-1Cell Line, TumorDNA-Binding ProteinsEstradiolEstrogen AntagonistsEstrogen Receptor alphaFemaleFulvestrantGene Expression RegulationGene Regulatory NetworksApoptosis Regulatory ProteinsBeclin-1BECN1 protein, humanDNA-Binding ProteinsEstradiolEstrogen AntagonistsEstrogen Receptor alphaFulvestrantInterferon Regulatory Factor-1IRF1 protein, humanMembrane ProteinsNF-kappa BRegulatory Factor X Transcription FactorsTranscription FactorsX-Box Binding Protein 1XBP1 protein, human

Identifiers

PMID19444933
PMCPMC2768542
OpenAlexW2058906289

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.